Stockscreener 앱 받기
41.18
6.07%
2.47
전일 마감가:
$38.71
열려 있는:
$39.09
하루 거래량:
1.57M
Relative Volume:
0.67
시가총액:
$4.78B
수익:
-
순이익/손실:
$-472.34M
주가수익비율:
-9.9327
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
+5.26%
1개월 성능:
+44.32%
6개월 성능:
+26.81%
1년 성능:
+49.25%
1일 변동 폭
$38.68
$41.66
1주일 범위
$36.69
$41.66
52주 변동 폭
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
41.14 | 4.35B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
520.05 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.42 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.09 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.95 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool
Piper Sandler reiterates Overweight on Viking Therapeutic stock - Investing.com
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? - AOL.com
Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation - simplywall.st
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030 - foreignpolicyjournal.com
OABI,VKTX Revenue Breakdown - Finviz
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Quick ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying - The Motley Fool
VKTXViking Therapeutics Inc Options - Finviz
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Here's Why Viking Therapeutics Stock Surged Higher in June - The Motley Fool
Viking Therapeutics, Inc. (VKTX) sees a more significant dip than broader market: Some facts to know - MSN
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Is Viking Therapeutics Stock Going to $100? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines - Yahoo Finance
Why Viking Therapeutics (VKTX) Is Up 22.2% After Advancing VK3019 Into First-in-Human Obesity Trial - Sahm
Cantor Fitzgerald reiterates Viking Therapeutic stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Viking Therapeutic stock rating at Overweight By Investing.com - Investing.com Canada
Viking Therapeutics holds at $5B valuation amid GLP-1 drug competition and awaits oral study results. - Pluang
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate (NASDAQ:VKTX) - Seeking Alpha
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
VKTX.O - Reuters
Is Viking Therapeutics stock a no-brainer buy below $35? - MSN
Is it worth investing in Viking Therapeutics (VKTX) based on Wall Street's bullish views? - MSN
(VKTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Yahoo Finance
Viking Therapeutics (VKTX) Starts A Phase 1 Obesity Trial, Is The Upside Already Priced In? - simplywall.st
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
ETFs Investing in Viking Therapeutics, Inc. Stocks - TradingView
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019 - Stocktwits
Enterprise value to EBITDA forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
A New Obesity Drug Just Reached Human Trials. Here's What Comes Next - Streetwise Reports
Price to earnings forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – FWB:1VT - TradingView
Price to sales forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Enterprise value to EBIT forward of Viking Therapeutics, Inc. – LS:A12GD6 - TradingView
Enterprise value to revenue forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
Price to sales forward of Viking Therapeutics, Inc. – FWB:1VT - TradingView
Price to book forward of Viking Therapeutics, Inc. – NASDAQ:VKTX - TradingView
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
VKTX Stock Price, Quote & Chart - ChartMill
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jan 05 '26 |
Sale |
32.90 |
57,661 |
1,896,969 |
189,891 |
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
1.16%
0.48%
자본화:
|
볼륨(24시간):